Industry-friendly reimbursement vital in Japan
This article was originally published in Clinica
Executive Summary
The availability of breakthrough medical technologies in Japan - the C2 category of product - could be improved by adopting reimbursement policies that are more responsive to innovation, industry believes. Industry and patients are currently impeded by the fact that C2 products are ineligible for reimbursement for at least two years after receipt of regulatory approval.